Gestational weight gain charts for different body mass index groups for women in Europe, North America, and Oceania by Santos, S. (Susana) et al.
RESEARCH ARTICLE Open Access
Gestational weight gain charts for different
body mass index groups for women in
Europe, North America, and Oceania
Susana Santos1,2, Iris Eekhout3,4, Ellis Voerman1,2, Romy Gaillard1,2, Henrique Barros5,6, Marie-Aline Charles7,8,
Leda Chatzi9,10,11, Cécile Chevrier12, George P. Chrousos13, Eva Corpeleijn14, Nathalie Costet12, Sarah Crozier15,
Myriam Doyon16, Merete Eggesbø17, Maria Pia Fantini18, Sara Farchi19, Francesco Forastiere19, Luigi Gagliardi20,
Vagelis Georgiu10, Keith M. Godfrey15,21, Davide Gori18, Veit Grote22, Wojciech Hanke23, Irva Hertz-Picciotto24,
Barbara Heude7,8, Marie-France Hivert16,25,26, Daniel Hryhorczuk27, Rae-Chi Huang28, Hazel Inskip15,21,
Todd A. Jusko29, Anne M. Karvonen30, Berthold Koletzko22, Leanne K. Küpers14,31,32, Hanna Lagström33,
Debbie A. Lawlor31,32, Irina Lehmann34, Maria-Jose Lopez-Espinosa35,36, Per Magnus37, Renata Majewska38,
Johanna Mäkelä39, Yannis Manios40, Sheila W. McDonald41, Monique Mommers42, Camilla S. Morgen43,44,
George Moschonis45, Ľubica Murínová46, John Newnham47, Ellen A. Nohr48, Anne-Marie Nybo Andersen44,
Emily Oken25, Adriëtte J. J. M. Oostvogels49, Agnieszka Pac38, Eleni Papadopoulou50, Juha Pekkanen30,51,
Costanza Pizzi52, Kinga Polanska23, Daniela Porta19, Lorenzo Richiardi52, Sheryl L. Rifas-Shiman25, Nel Roeleveld53,
Loreto Santa-Marina36,54,55, Ana C. Santos5,6, Henriette A. Smit56, Thorkild I. A. Sørensen44,57, Marie Standl58,
Maggie Stanislawski59, Camilla Stoltenberg60,61, Elisabeth Thiering58,62, Carel Thijs42, Maties Torrent63,
Suzanne C. Tough41,64, Tomas Trnovec65, Marleen M. H. J. van Gelder53,66, Lenie van Rossem56, Andrea von Berg67,
Martine Vrijheid36,68,69, Tanja G. M. Vrijkotte49, Oleksandr Zvinchuk70, Stef van Buuren3,71 and
Vincent W. V. Jaddoe1,2,72*
Abstract
Background: Gestational weight gain differs according to pre-pregnancy body mass index and is related to the
risks of adverse maternal and child health outcomes. Gestational weight gain charts for women in different pre-
pregnancy body mass index groups enable identification of women and offspring at risk for adverse health outcomes.
We aimed to construct gestational weight gain reference charts for underweight, normal weight, overweight, and
grades 1, 2 and 3 obese women and to compare these charts with those obtained in women with uncomplicated
term pregnancies.
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Methods: We used individual participant data from 218,216 pregnant women participating in 33 cohorts from Europe,
North America, and Oceania. Of these women, 9065 (4.2%), 148,697 (68.1%), 42,678 (19.6%), 13,084 (6.0%), 3597 (1.6%),
and 1095 (0.5%) were underweight, normal weight, overweight, and grades 1, 2, and 3 obese women, respectively. A
total of 138, 517 women from 26 cohorts had pregnancies with no hypertensive or diabetic disorders and with term
deliveries of appropriate for gestational age at birth infants. Gestational weight gain charts for underweight, normal
weight, overweight, and grade 1, 2, and 3 obese women were derived by the Box-Cox t method using the generalized
additive model for location, scale, and shape.
Results: We observed that gestational weight gain strongly differed per maternal pre-pregnancy body mass index
group. The median (interquartile range) gestational weight gain at 40 weeks was 14.2 kg (11.4–17.4) for underweight
women, 14.5 kg (11.5–17.7) for normal weight women, 13.9 kg (10.1–17.9) for overweight women, and 11.2 kg
(7.0–15.7), 8.7 kg (4.3–13.4) and 6.3 kg (1.9–11.1) for grades 1, 2, and 3 obese women, respectively. The rate of
weight gain was lower in the first half than in the second half of pregnancy. No differences in the patterns of
weight gain were observed between cohorts or countries. Similar weight gain patterns were observed in mothers
without pregnancy complications.
Conclusions: Gestational weight gain patterns are strongly related to pre-pregnancy body mass index. The derived
charts can be used to assess gestational weight gain in etiological research and as a monitoring tool for weight gain
during pregnancy in clinical practice.
Keywords: Weight gain, Pregnancy, Charts, References
Background
Gestational weight gain is an important predictor of ad-
verse maternal and child health outcomes [1]. Insuffi-
cient weight gain is associated with increased risks of
preterm birth and delivering a low birth weight infant,
whereas excessive weight gain is associated with in-
creased risks of gestational hypertension, preterm birth,
delivering a high birth weight infant, cesarean delivery,
and childhood overweight [2–5].
Appropriate gestational weight gain charts are neces-
sary to monitor the progress of weight gain and to en-
able risk selection. Gestational weight gain charts have
been derived from country-specific studies that varied in
sample selection, study design, and methods of data col-
lection and statistical analysis [6]. A study of the
INTERGROWTH-21st Project among 3097 normal
weight women from Brazil, China, India, Italy, Kenya,
Oman, UK, and USA described the patterns in maternal
gestational weight gain from 14 weeks onwards in
healthy pregnancies with good maternal and perinatal
outcomes [7]. Another previous hospital-based study de-
veloped gestational weight gain charts for 4246 over-
weight and obese US women, respectively, delivering
uncomplicated term pregnancies [8]. Also, weight gain
for gestational age charts for underweight, normal
weight, overweight, and grades 1, 2, and 3 obese women
were created in a large population-based cohort of
141,767 Swedish women with term, non-anomalous,
singleton pregnancies and no pre-existing hypertension
or diabetes [9]. Results from these studies showed the
strong influence of pre-pregnancy body mass index
(BMI) on gestational weight gain. The generalizability of
these charts to other populations is not known. Inter-
national gestational weight gain charts for specific
pre-pregnancy BMI groups are important to improve
clinical monitoring and risk selection of pregnant
women.
We used individual participant data from 218,216
pregnant women from 33 European, North American,
and Oceania pregnancy cohort studies to assess the pat-
tern of weight gain and to construct gestational weight
gain charts for underweight, normal weight, overweight,
and grades 1, 2, and 3 obese women. Additionally, we
compared these charts to those obtained in 138,517
pregnant women from 26 cohorts who had uncompli-
cated term pregnancies.
Methods
Inclusion criteria and participating cohorts
This study was embedded in an international collabor-
ation on Maternal Obesity and Childhood Outcomes
(MOCO). Pregnancy and birth cohort studies partici-
pated if they included mothers with singleton live-born
children born from 1989 onwards, had information
available on maternal pre/early-pregnancy BMI and at
least one offspring measurement (birth weight or child-
hood BMI) and were approved by their local institutional
review boards. We identified 50 cohorts from Europe,
North America, and Oceania selected from the existing
collaborations on childhood health (EarlyNutrition Pro-
ject, CHICOS Project, www.birthcohorts.net assessed
until July 2014). We invited these cohorts, of which 39
cohorts agreed to participate, providing data of 239,621
singleton births. Detailed information on these cohorts
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can be found in www.birthcohorts.net. We included co-
horts with information on pre-pregnancy BMI and
weight measurements throughout pregnancy with infor-
mation on the corresponding gestational age (33 co-
horts). Per cohort, women were included if they had
pre-pregnancy BMI to allow classification into the spe-
cific pre-pregnancy BMI groups. Therefore, all women
had information on weight at 0 weeks, which refers to
pre-pregnancy weight. Since the data were modeled
cross-sectionally, no further restriction was applied re-
garding the weight measurements throughout preg-
nancy. Our final sample comprised 33 cohorts and
218,216 women who contributed with 679,262 gesta-
tional weight measurements, of which 218,216 at 0 weeks
and 461,046 throughout pregnancy. Of these women,
9065 (4.2%), 148,697 (68.1%), 42,678 (19.6%), 13,084
(6.0%), 3597 (1.6%), and 1095 (0.5%) were underweight,
normal weight, overweight, obese grade 1, obese grade 2,
and obese grade 3, respectively (flow chart is given in
Additional file 1: Figure S1). Twenty-seven of the 33 co-
horts defined themselves as regionally or nationally
based studies, four as hospital-based (Co.N.ER, EDEN,
GASPII, LUKAS), one as internet users-based (NIN-
FEA), and one as studying selected populations (FCOU).
To also obtain the charts in uncomplicated pregnancies,
we further restricted our sample to women who had
pregnancies with no hypertensive or diabetic disorders
and with term deliveries of appropriate for gestational
age at birth infants. This sample of uncomplicated term
pregnancies comprised 26 cohorts and 138, 517 women,
of which 5541, 97,263, 26,320, 7160, 1752, and 481 were
underweight, normal weight, overweight, and obese
grades 1, 2 and 3, respectively. Anonymized datasets
were stored on a single central secured data server with
access for the main analysts (SS, IE).
Maternal anthropometrics
Maternal anthropometrics were measured, derived from
clinical records or self-reported (cohort-specific informa-
tion is shown in Additional file 1: Table S1). Maternal
pre-pregnancy BMI was calculated from information on
height and weight before pregnancy and was categorized
as underweight (< 18.5 kg/m2), normal weight (18.5–
24.9 kg/m2), overweight (25.0–29.9 kg/m2), obesity grade
1 (30.0–34.9 kg/m2), obesity grade 2 (35.0–39.9 kg/m2),
and obesity grade 3 (≥ 40.0 kg/m2) according to the
World Health Organization criteria [10]. Data were ob-
tained on early, mid, and late pregnancy weight as the
closest measurement to 13 weeks of gestation (range 6–
19.9 weeks of gestation), the closest measurement to
26 weeks of gestation (range 20–31.9 weeks of gesta-
tion), and the closest measurement to 40 weeks of gesta-
tion (range 32–45 weeks of gestation). For the
construction of the charts, we created, in a long data
format, one single weight variable with the correspond-
ing gestational age. Then, weight gain was calculated as
the difference between the weight at certain gestational
age and the pre-pregnancy weight. Cohort-specific infor-
mation on the methods used to estimate gestational age
is shown in Additional file 1: Table S1.
Statistical analysis
We modeled gestational weight gain by gestational age
separately for each maternal pre-pregnancy BMI group
to develop the pre-pregnancy BMI group-specific gesta-
tional weight gain charts. We had available weight mea-
surements at the start of pregnancy and subsequent
weights from 8 weeks onwards. For that reason, we
modeled from the week 0 onwards. We initially fitted
the model in which each woman had a weight gain of
0 kg at the start of pregnancy (0 weeks), but the lack of
variation in the outcome caused severe numerical prob-
lems. To address this, we imagined a nudge effect equal
to the measurement error of body weight. It is known
that measurement error of a single dial measurement is
about 0.70 kg [11], so the variance of the gain score is
equal to 0.702 + 0.702 = 0.98 kg. For each woman, the
weight gain at the start of pregnancy was taken as a ran-
dom draw from the Gaussian distribution with mean of
0 and variance of 0.98 kg. The size of the measurement
error was used since it is theoretically based but any
variance could have been applied. We started the model-
ing using a Box-Cox Cole and Green distribution (Box--
Cox normal), which turned out to be too strict to fit the
data. Therefore, we fitted the models, separately for each
maternal pre-pregnancy BMI group, by the Box-Cox t
(BCT) method using the generalized additive model for
location, scale, and shape (GAMLSS) package in R ver-
sion 3.3.1 [12]. We used GAMLSS instead of quantile re-
gression since in the latter the centiles are estimated
individually and thus may cross, leading to an invalid
distribution for the outcome. Additionally, there are no
distributional assumptions in quantile regression, which
may hamper the estimation of the outer centiles with
sufficient precision even when there is enough informa-
tion at the tails [13]. In the BCT method, the default
links from the GAMLSS package, namely, an identity
link for the mu and nu parts and a log link for the sigma
and tau parts of the model, were used. The BCT method
summarizes the distribution in four time-dependent
smooth curves representing the median (M-curve), the
variation (S-curve), the skewness (L-curve), and the kur-
tosis (T-curve) [14]. The smoothing family and the
amount of smoothing were determined by visual inspec-
tion of the worm plots, the fitted centiles, and the Q sta-
tistics [15, 16]. The worm plots describe salient features
of the time-conditional z score distribution and aid in
finding proper smoothing values for the model [15].The
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M-curve of the models for weight gain was fitted using
B-splines smoothing on gestational age with specified in-
ternal breakpoints to define the splines and three de-
grees which is similar to a cubic spline. Cubic splines
smoothing on gestational age was also used for the
S-curve, L-curve, and T-curve. The models for the dif-
ferent maternal pre-pregnancy BMI groups were fitted
with different internal breakpoints and degrees of free-
dom for the curves. Model specifications for each BMI
group are given in Additional file 1: Table S2. Data were
modeled cross-sectionally since taking the correlation
between repeated observations of the same individual
into account seems to have negligible effects on the lo-
cation and precision of the centiles [13]. We tested for
pre-pregnancy weight as well as cohort and country dif-
ferences in the models. To confirm that using a more
advanced model was justified, we tested for each mater-
nal pre-pregnancy BMI group whether our model had a
better fit as compared to a simple linear model using the
Bayesian information criterion. We also compared our
charts to those obtained, using the same analytical strat-
egy and models, in a sample restricted to women who
had uncomplicated term pregnancies.
Results
Subject characteristics
Characteristics of the participating pregnancy cohorts are
given in Table 1. Overall, the median maternal
pre-pregnancy BMI and total gestational weight gain were
22.7 kg/m2 (interquartile range 20.8–25.4 kg/m2) and
14.0 kg (interquartile range 11.0–17.9 kg), respectively. The
number of weight measurements during pregnancy avail-
able per participating cohort and per maternal
pre-pregnancy BMI group is given in Additional file 1:
Table S3. The overall sample size according to gestational
age for each maternal pre-pregnancy BMI group is shown
in Additional file 1: Figure S2. For the construction of the
charts, most weight measurements were available around
15, 30, and 40 weeks of gestation and for normal weight
and overweight women.
Gestational weight gain charts
Figure 1 shows selected percentiles of weight gain for
gestational age (P2.3 (− 2 SD), P16 (− 1 SD), P50 (0 SD),
P84 (1 SD), and P97.7 (2 SD)) for underweight, normal
weight, overweight, and grades 1, 2, and 3 obese women.
Gestational weight gain strongly differed per maternal
pre-pregnancy BMI group and was gradually lower
across higher BMI groups. The median (interquartile
range) gestational weight gain at 40 weeks was 14.2 kg
(11.4–17.4) for underweight women; 14.5 kg (11.5–17.7)
for normal weight women; 13.9 kg (10.1–17.9) for over-
weight women; and 11.2 kg (7.0–15.7), 8.7 kg (4.3–13.4),
and 6.3 kg (1.9–11.1) for grades 1, 2, and 3 obese
women, respectively. For all maternal pre-pregnancy
BMI groups, weight gain trajectories throughout preg-
nancy followed a non-linear shape. The Bayesian infor-
mation criterion supported our non-linear model that
showed a better statistical fit as compared to a simple
linear model. The rate of weight gain was lower in the
first half than in the second half of pregnancy for all
pre-pregnancy BMI groups. Especially in overweight
women, we observed a higher rate of weight gain around
22–25 weeks of gestation. The coefficients of variation
between pre-pregnancy weights within the same BMI
group, and between cohorts and countries were smaller
than the measurement error (variance of the weight gain
of 0.98 kg), reinforcing the similarities in the charts for
the variety of weights within each BMI group and
among cohorts and countries. These findings also sug-
gest no strong cohort birth period or region effects on
our charts. The predicted z scores for the average weight
gain according to gestational age for each maternal BMI
group are shown in Additional file 1: Figure S3. Only a
small misfit, caused by less data available, was observed
for grade 3 obese women. Estimates of weight gain for
selected percentiles according to gestational age and ma-
ternal BMI groups are given in Additional file 1: Tables
S4-S9. Figure 2 shows the equation for the calculation of
z scores based on a BCT model. The parameters of our
BCT model at a certain gestational age to allow the cal-
culation of z scores are given in Additional file 1: Tables
S4-S9 (available in an excel spreadsheet upon request).
An online tool to produce individual z scores and per-
centiles for gestational weight gain in singleton pregnan-
cies based on our international reference charts is
available at https://lifecycle-project.eu.
Similar charts were obtained when we applied the same
models to a sample without pregnancy complications (Fig. 3).
We also observed similar estimates of weight gain for P50 at
20 and 40 weeks of gestation for all maternal pre-pregnancy
BMI groups in all pregnant women and in women without
any pregnancy complication. Although the estimates were
largely similar, we observed that women without any preg-
nancy complication who were underweight or normal
weight tended to gain higher weight and those who were
overweight or obese tended to gain lower weight, compared
to the full group of pregnant women (Table 2). Similar re-
sults were observed when restricting all analyses to the re-
gionally and nationally based cohorts (data not shown).
Discussion
In this study, we developed gestational weight gain charts
for different pre-pregnancy BMI groups for women in
Europe, North America, and Oceania. Gestational weight
gain strongly differed per maternal pre-pregnancy BMI
group and was gradually lower across higher BMI groups.
For all maternal BMI groups, weight gain throughout
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Table 1 Characteristics of the participating pregnancy cohorts (n = 218,216)a
Cohort name, number of participants, birth years
(country)
Maternal pre-pregnancy body mass index
(kg/m2)
Maternal total gestational weight gain
(kg)
Gestational age at birth
(weeks)
ABCD, n = 7820, 2003–2004
(The Netherlands)
22.3 (20.5, 24.8) NA 40.0 (39.0, 41.0)
ALSPAC, n = 11,344, 1991–1992
(UK)
22.2 (20.5, 24.4) 12.5 (9.5, 15.5) 40.0 (39.0, 41.0)
AOB/F, n = 2941, 2008–2010
(Canada)
23.0 (20.8, 26.3) NA 39.0 (38.0, 40.0)
Co.N.ER, n = 637, 2004–2005
(Italy)
21.1 (19.7, 23.4) 13.0 (10.0, 16.0) 39.0 (39.0, 40.0)
DNBC, n = 42,761, 1996–2002
(Denmark)b
22.5 (20.7, 25.1) 15.0 (12.0, 18.0) 40.1 (39.1, 41.0)
EDEN, n = 1875, 2003–2005
(France)
22.1 (20.1, 25.3) 13.0 (11.0, 16.3) 39.0 (39.0, 40.0)
FCOU, n = 3650, 1993–1996
(Ukraine)
21.6 (19.8, 24.0) 12.0 (9.2, 15.0) 40.0 (39.0, 41.0)
GASPII, n = 675, 2003–2004
(Italy)
21.3 (19.8, 23.6) 13.0 (10.5, 16.0) 40.0 (39.0, 41.0)
GECKO Drenthe, n = 2501, 2006–2007 (The
Netherlands)
23.7 (21.5, 26.8) 13.0 (10.0, 17.0) 40.0 (39.0, 40.9)
Generation R, n = 7183 2002–2006 (The Netherlands) 22.6 (20.8, 25.4) 12.0 (9.0, 16.0) 40.1 (39.0, 41.0)
Generation XXI, n = 7621, 2005–2006 (Portugal) 22.9 (21.0, 25.8) 13.0 (10.0, 17.0) 39.0 (38.0, 40.0)
GENESIS, n = 2218, 2003–2004
(Greece)
21.9 (20.2, 24.0) 13.0 (10.0, 17.0) 40.0 (39.0, 40.0)
Gen3G, n = 846, 2010–2013
(Canada)
23.3 (20.9, 27.3) 13.7 (10.7, 17.0) 39.4 (38.5, 40.2)
GINIplus, n = 2329, 1995–1998
(Germany)
22.1 (20.4, 24.2) 13.0 (10.0, 15.7) 40.0 (39.0, 41.0)
HUMIS, n = 1067, 2003–2008
(Norway)
23.5 (21.3, 26.2) 14.0 (11.0, 18.0) 40.1 (39.0, 41.1)
INMA, n = 2561, 1997–2008
(Spain)
22.5 (20.7, 25.0) 13.5 (10.5, 16.6) 39.9 (38.9, 40.6)
KOALA, n = 2812, 2000–2002
(The Netherlands)
22.7 (20.9, 25.3) 14.0 (11.0, 17.0) 40.0 (39.0, 40.0)
Krakow Cohort, n = 503,
2000–2003 (Poland)
21.0 (19.5, 22.7) 15.0 (12.0, 18.0) 40.0 (39.0, 40.0)
LISAplus, n = 2962, 1997–1999
(Germany)
21.7 (20.2, 24.1) 14.0 (11.5, 17.0) 40.0 (39.0, 41.0)
LUKAS, n = 417, 2002–2005
(Finland)
24.1 (21.9, 27.2) 13.8 (10.9, 17.8) 40.0 (39.0, 40.0)
MoBa, n = 88,503, 1999–2009
(Norway)
23.1 (21.1, 25.9) 15.0 (11.0, 18.0) 40.1 (39.1, 41.0)
NINFEA, n = 2237, 2005–2010
(Italy)c
21.4 (19.9, 23.9) 12.0 (10.0, 15.0) 39.7 (38.9, 40.7)
PÉLAGIE, n = 1490, 2002–2005
(France)
21.6 (20.0, 23.8) NA 40.0 (39.0, 40.0)
PIAMA, n = 3459, 1996–1997
(The Netherlands)
22.2 (20.6, 24.3) 13.0 (10.0, 16.0) 40.0 (39.1, 40.9)
Piccolipiù, n = 3294, 2011–2015
(Italy)
21.7 (19.9, 24.2) 13.0 (10.0, 15.0) 39.0 (39.0, 40.0)
PRIDE Study, n = 1513, 2011–2015
(The Netherlands)
22.5 (20.7, 24.8) 14.0 (11.0, 17.0) 39.0 (39.0, 40.0)
Project Viva, n = 2106,
1999–2002 (United States)
23.5 (21.0, 27.3) 15.5 (12.3, 19.1) 39.7 (38.9, 40.6)
Raine Study, n = 2791,
1989–1992 (Australia)
21.3 (19.6, 23.7) NA 39.0 (38.0, 40.0)
REPRO_PL, n = 1409,
2007–2011(Poland)
21.5 (19.8, 23.8) 12.0 (9.0, 15.0) 39.0 (38.5, 40.0)
RHEA, n = 816, 2007–2008
(Greece)
23.3 (21.2, 26.2) 13.0 (10.0, 17.0) 38.0 (38.0, 39.0)
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pregnancy followed a non-linear trajectory. The rate of
weight gain was greater in the second than in the first half
of pregnancy. No differences in the patterns of weight gain
were observed between cohorts or countries. Our refer-
ence charts were largely similar to those obtained in a
sample restricted to uncomplicated term pregnancies.
Interpretation of main findings
Gestational weight gain is an important predictor of ad-
verse maternal and child health outcomes [1]. Weight
gain reflects multiple components. It has been suggested
that about 30% of gestational weight gain comprises the
fetus, amniotic fluid, and placenta, whereas the
Table 1 Characteristics of the participating pregnancy cohorts (n = 218,216)a (Continued)
Cohort name, number of participants, birth years
(country)
Maternal pre-pregnancy body mass index
(kg/m2)
Maternal total gestational weight gain
(kg)
Gestational age at birth
(weeks)
Slovak PCB study, n = 1048, 2002–2004 (Slovakia) 21.2 (19.5, 24.0) 13.0 (10.0, 17.0) 40.0 (39.0, 40.0)
STEPS, n = 1708, 2008–2010
(Finland)
23.0 (21.1, 26.1) 13.9 (10.8, 17.4) 40.0 (39.0, 41.0)
SWS, n = 3119, 1998–2007
(UK)
24.1 (21.9, 27.4) 11.9 (8.3, 15.7) 40.0 (39.0, 41.0)
Total group 22.7 (20.8, 25.4) 14.0 (11.0, 17.9) 40.0 (39.0, 41.0)
aValues are expressed as medians (interquartile range). NA not available
bSubset of participants with offspring body mass index available at 7 years by the time of data transfer (May 2015)
cSubset of participants with follow-up completed at 4 years of child’s age by the time of data transfer (March 2015)
Fig. 1 Selected percentiles of weight gain for gestational age for maternal pre-pregnancy underweight (a), normal weight (b), overweight (c),
obesity grade 1 (d), obesity grade 2 (e) and obesity grade 3 (f)
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remaining 70% comprises uterine and mammary tissue
expansion, increased blood volume, extracellular fluid,
and fat stores [17]. The US Institute of Medicine (IOM)
published in 2009 the revised recommended gestational
weight gain ranges, i.e., 12.5–18 kg, 11.5–16 kg, 7–
11.5 kg, and 5–9 kg for underweight, normal weight,
overweight, and obese women, respectively, based on
findings from observational studies focused on associa-
tions of gestational weight gain with preterm birth,
small, and large size for gestational age at birth, cesarean
delivery, postpartum weight retention, and childhood
obesity [1]. Both insufficient and excessive gestational
weight gain, defined according to these guidelines, are
risk factors of adverse maternal and child health out-
comes [2–5]. In our study, insufficient, adequate, and ex-
cessive gestational weight gain was observed in 38.1%,
43.8%, and 18.1% of underweight women; 25.4%, 41.5%,
and 33.1% of normal weight women; 9.8%, 24.3%, and
65.9% of overweight women; and 18.6%, 24.0%, and
57.4% of obese women, respectively.
Gestational weight gain charts are important from a
clinical and epidemiological perspective. From a clinical
perspective, appropriate gestational weight gain charts
can help to identify individuals at risk for adverse health
outcomes. It has been recognized that it might be prob-
lematic to link total gestational weight gain with preg-
nancy outcomes that are highly correlated with
gestational age at birth, such as preterm birth. Women
who deliver at earlier gestational ages have less time to
gain weight, which may lead to a spurious association
between low gestational weight gain and preterm birth.
The use of the rate of weight gain (kg per week of gesta-
tion) reduces but does not entirely resolve this bias [2].
Weight gain for gestational age z score charts can be
used to classify weight gain independently of gestational
age and provide a tool to establish the unbiased associa-
tions between gestational weight gain and pregnancy
outcomes. This method enables comparison of weight
gain of women who deliver at earlier gestational ages
with weight gain of women with normal pregnancy dur-
ation at the same point in pregnancy. Although various
gestational weight gain charts have previously been de-
veloped, these charts vary across different studies and
still have methodological limitations [7–9, 18–29]. Based
on a recent systematic review of 12 studies involving
2,268,556 women from 9 countries, differences in the
methodological quality of gestational weight gain studies
may explain the varying chart recommendations. These
charts were all derived from country-specific studies that
varied in sample selection, study design, methods of data
collection, and statistical analysis [6]. A study among
3097 normal weight women from Brazil, China, India,
Italy, Kenya, Oman, UK, and USA described the patterns
in maternal gestational weight gain from 14 weeks on-
wards in healthy pregnancies with good maternal and
perinatal outcomes. The authors suggested that weight
gain follows a linear trajectory throughout pregnancy,
which was similar across the eight populations [7]. A
hospital-based study developed gestational weight gain
charts for 1047, 1202, 1267, and 730 overweight, grades
1, 2, and 3 obese US women, respectively, delivering un-
complicated term pregnancies. The rate of weight gain
was minimal until 15–20 weeks and then increased in a
slow, linear manner until term. The rate of weight gain
was lower as BMI increased [8]. In a study among
141,767 Swedish women with term, non-anomalous,
singleton pregnancies and no pre-existing hypertension
or diabetes, the rate of weight gain also decreased with
increasing BMI. In normal weight, overweight and grade
1 obese women, the median rate of weight gain was
Fig. 2 Equation for the calculation of pre-pregnancy body mass index-specific gestational weight gain z scores based on a Box-Cox t modela.
awhere Y is weight gain at a certain gestational age, L is lambda, M is mu, and S is sigma. The random variable Z is assumed to follow a t
distribution with degrees of freedom, Tau > 0, treated as a continuous parameter. The parameters of our Box-Cox t model for each pre-pregnancy
body mass index group are provided for the rounded gestational ages. This equation can be applied on data using the y2z function of the AGD
package in R. The function will allow the calculation of z scores for the exact gestational age by extrapolating the parameters. For applying the
equation or function, weight gain must be > 0, because the model cannot deal with negative values. In order to fit the Box-Cox t model,
parameters were calculated based on weight gain + 20 kg, and thus 20 kg must be added to weight gain to be able to use our parameters. The
constant of 20 kg was chosen since − 20 kg is an extremely low value for weight change during pregnancy. After adding the 20 kg, weight gain
must be > 0; otherwise, the equation or function using our Box-Cox t model parameters cannot be applied for the remaining ≤ 0 values
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Table 2 Percentile 50 of gestational weight gain at 20 and 40 weeks for maternal pre-pregnancy body mass index groups in all
pregnant women and in women without any pregnancy complication
P50 of weight gain (kg) at 20 weeks P50 of weight gain (kg) at 40 weeks
All pregnant
women
Women without any pregnancy
complication
All pregnant
women
Women without any pregnancy
complication
Underweight 4.20 4.17 14.20 14.47
Normal weight 3.90 3.91 14.49 14.53
Overweight 3.35 3.28 13.86 13.68
Obesity grade
1
1.95 1.93 11.19 10.99
Obesity grade
2
0.93 0.34 8.73 8.02
Obesity grade
3
−0.35 −0.49 6.27 5.65
Fig. 3 Selected percentiles of weight gain for gestational age in women without any pregnancy complication for maternal pre-pregnancy
underweight (a), normal weight (b), overweight (c), obesity grade 1 (d), obesity grade 2 (e) and obesity grade 3 (f)
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minimal until 15 weeks, after which it increased in a lin-
ear manner until term whereas in underweight, and
grades 2 and 3 obese women, the median rate of weight
gain was steady throughout gestation [9]. The
generalizability of these charts to other populations is
not known.
In the current study, we constructed gestational weight
gain reference charts for 218,216 underweight, normal
weight, overweight, and grades 1, 2, and 3 obese women
using data from cohorts from Europe, North America,
and Oceania. We observed that for all maternal
pre-pregnancy BMI groups, weight gain throughout
pregnancy followed a non-linear trajectory. This finding
is not consistent with results of previous studies that
suggested that weight gain follows a linear trajectory at
least from the second half of pregnancy onwards [7–9].
We included a large spectrum of gestational age and had
a large number of participants and weight measurements
available, enabling the detection of small variations in
the weight gain patterns. The non-linearity of the trajec-
tories was supported by advanced visual diagnostic
methods for model choice and information criteria. This
difference in the pattern of weight gain between our
study and previous studies is not a result of longitudinal
or cross-sectional modeling since the inclusion of the
correlation structure among observations seems to have
negligible effects on the location and precision of the
centiles [13]. Therefore, from a statistical point of view,
we believe that these charts describe the actual track of
weight gain during pregnancy and that a simpler method
assuming a linear weight gain fits the data less well.
From a biological point of view, gestational weight gain
reflects multiple fetal and maternal components [17].
This non-linearity might be the result of fluctuations in
these components throughout pregnancy. This variation
in the weight gain seems to be more pronounced in the
obese groups. Also, contributing to this non-linearity, we
observed a greater rate of weight gain around 22–
25 weeks, especially in overweight women, which might
be related to the initiation of adipose tissue formation in
the fetus that is known to occur between the 14th and
the 23rd week of gestation [30]. In the current study, the
rate of weight gain was greater in the second than in the
first half of pregnancy and was lower as pre-pregnancy
BMI was higher. Despite the range of cultures, behav-
iors, clinical practices, and traditions, which can strongly
influence gestational weight gain, we did not observe dif-
ferences in the patterns of weight gain between cohorts
and countries. This finding might indicate that the bio-
logical process of gaining weight during pregnancy does
not differ across different international populations in
Europe, North America, and Oceania.
Gestational weight gain charts can be classified as ref-
erence charts or standard charts. A reference chart is
based on a sample of the general population and is de-
scriptive, whereas a standard chart is only focused on a
healthy population and is prescriptive. The use of refer-
ences or standards might influence the chart recommen-
dations. Gestational weight gain standards might be
biased by the definition of what constitutes a healthy
population, especially for overweight and obese women,
and might be compromised by an inadequate sample
size. The INTERGROWTH-21st Project developed stan-
dards in an international population of normal weight
women by only including women with healthy pregnan-
cies with good maternal and perinatal outcomes [7].
However, a recent study showed that the
INTERGROWTH-21st standards do not seem to de-
scribe optimal weight gain patterns with respect to ma-
ternal postpartum weight retention and thus may still be
descriptive [31]. We developed gestational weight gain
reference charts by including all pregnant women that
had all necessary information available for these analyses
and compared with the charts obtained in a sample with
good maternal and perinatal outcomes. We observed
similar weight gain patterns for each maternal BMI
group in all pregnant women and in women without any
pregnancy complication. Thus, our reference charts are
largely similar to those obtained in a sample restricted
to uncomplicated term pregnancies, were developed in a
large sample, enabling relatively accurate charts for
women with severe obesity, and were less likely to bias
in the definition of the population. We consider our ref-
erence charts as appropriate charts for clinical practice
and epidemiological research. However, future studies
are needed to relate the derived reference charts to ma-
ternal and offspring outcomes and to create customized
weight gain charts by including factors such as parity
and ethnicity. Finally, since the causality for the associa-
tions of maternal gestational weight gain with maternal
and child’s health outcomes remain unclear, practicing
prenatal care on weight gain is still debatable [32, 33]. A
further unanswered question is whether alteration of
these gestational weight gain patterns is achievable as, to
date, randomized controlled trials focused on lifestyle in-
terventions during pregnancy have shown only small re-
ductions in gestational weight gain [33–35].
Strengths and limitations
Strengths of this study were the description of the pat-
tern of weight gain throughout pregnancy in a large
sample of pregnant women from 33 cohorts from Eur-
ope, North America, and Oceania. However, our chart
for grade 3 obese women would have benefited from a
larger sample and thus the values of selected percentiles
in our chart may differ from the true values in the
underlying population. We included data from cohort
studies from Europe, North America, and Oceania but a
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large proportion of data come from Northern Europe.
This suggests that our charts might be generalizable to
Western populations and specifically to populations of
Northern European ancestry. Further studies are needed
to develop gestational weight gain charts among popula-
tions from low- to middle-income countries and of differ-
ent ethnic backgrounds. Since most studies were general
population-based cohort studies, we might have an over-
representation of the healthier population due to selective
non-response in the participating cohorts. This might
have underestimated the prevalence of inadequate and ex-
cessive gestational weight gain and of the adverse health
outcomes. However, we observed similar findings in the
full group and when we restricted our analyses to women
with uncomplicated pregnancies, which suggest no strong
bias due to selection in the cohorts. Also, due to the data
request format within this collaboration, only one weight
measurement at early, mid, and late pregnancy was ob-
tained, when available, for each woman even if multiple
weight measurements were taken during each period. This
might have limited the number of weight measurements
available for the creation of these charts. For our analyses,
we had available weight measurements at the start of
pregnancy and subsequent weights from 8 weeks onwards.
The lack of weight measurements during the beginning of
pregnancy could have influenced the modeling of weight
gain patterns, but we believe this is unlikely since not
much variation is expected during this period. The correl-
ation between weight at the start of pregnancy and weight
at 8 weeks of gestation was 0.99 and an intraclass correl-
ation coefficient using an absolute agreement definition of
97.9% was obtained through a two-way mixed effects
model. Finally, we relied not only on weight data obtained
by measurements and derived from clinical records but
also on self-reported data, which might be a source of
error. Women tend to underestimate their weight on
self-report [36]. An underestimation of pre-pregnancy
weight might lead to a misclassification of women in the
different BMI groups and to an overestimation of weight
gain at each specific week of gestation. Since measured
pre-pregnancy weight is rarely available in routine clinical
practice, our reference charts reflect the information usu-
ally used to assess weight gain in the prenatal care.
Methods of gestational age assessment might also be
prone to error, leading to some inaccuracy in the gesta-
tional weight gain percentiles and z scores, though the
error in gestational age estimates and thus the influence
on our results is likely to be small. For the construction of
the standards, we excluded women based on direct
pregnancy-related complications, such as hypertensive or
diabetic disorders, preterm deliveries, and small or large
for gestational age at birth infants. Unfortunately, infor-
mation about excess postpartum weight retention and in-
fant deaths was not available.
Conclusions
We developed gestational weight gain reference charts
for different pre-pregnancy BMI groups for women in
Europe, North America, and Oceania. Gestational weight
gain strongly differed per maternal pre-pregnancy BMI
group and was gradually lower across higher BMI
groups. These reference charts can be used to classify
weight gain independently of gestational age in etio-
logical research focused on maternal and offspring con-
sequences of weight gain. Future research is needed that
relates these charts with a broad range of maternal and
child health outcomes. These charts may be useful in
clinical practice to identify women at risk for adverse
short- and long-term health outcomes.
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